Date:	31/3/2024		
Your Name:	Liyuan Zhu		
Manuscript Title:	<u>Intravenous immunoglobuli</u>	lin can induce antibody-dependent cell-mediated cytotoxicity and	
upregulate FCGR3/	A and FcyRIIIA expression in	n vitro	
Manuscript numbe	r (if known):AOB-	-23-42	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		-	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	Fundings: Medical and	
	manuscript (e.g., funding,	Health Science and	
	provision of study materials,	Technology Innovation	
	medical writing, article	Project, Chinese Academy	
	processing charges, etc.)	of Medical Sciences (Grant	
	No time limit for this item.	Nos. 2021-12M-I-060 and	
		2021-12M-1-042), the	
		NMPA Key Laboratory of	
		Quality Control of Blood	
		Products (supported by	
		the Guangdong Institute	
		for Drug Control) (Grant	
		No. KF2021011), and the	
		Sichuan Science and	
		Technology Program	
		(Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
U	testimony	None	
	testimony		
7	Support for attending	None	
•	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	Nana	
11	Stock or stock options	None	
12	Receipt of equipment,	Ye Gang, an employee of	
	materials, drugs, medical	Zhengzhou RAAS Blood	
	writing, gifts or other	Products Co., Ltd,	
	services	provided part of the	
		materials and drugs,	
		including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date:	-	31/3/2024	
Your Name:	_Yafei Zhao _		
Manuscript Title:_	Intravenous	immunoglobulin can i	nduce antibody-dependent cell-mediated cytotoxicity and
upregulate FCGR3	A and FcyRIII	A expression in vitro	
Manuscript number	er (if known):	AOB-23-42_	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert	None	
	testimony		
_			
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date:	31/3/2024	
Your Name:	Gang Ye	
Manuscript Title:	Intravenous immunoglob	oulin can induce antibody-dependent cell-mediated cytotoxicity and
upregulate FCGR3	A and FcyRIIIA expression	n in vitro
Manuscript number	r (if known):AOI	DB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	Nana	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY. GY serves as an employee of Zhengzhou RAAS Blood Products Co., Ltd.

Please place an "X" next to the following statement to indicate your agreement:

Date:	31/3/2024
Your Name:	_Yuwei Huang
Manuscript Title:_	Intravenous immunoglobulin can induce antibody-dependent cell-mediated cytotoxicity and
upregulate FCGR3	SA and FcyRIIIA expression in vitro
Manuscript number	er (if known):AOB-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated	None	

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
5	lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Ye Gang, an employee of	
12	materials, drugs, medical	Zhengzhou RAAS Blood	
	writing, gifts or other	Products Co., Ltd,	
	services	provided part of the	
		materials and drugs,	
		including IVIG.	
13	Other financial or non-	None	
13	financial interests	None	
	manda microsts		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date:	31,	/3/2024	
Your Name:	Qing Liu		
Manuscript Title:	Intravenous imr	munoglobulin can inc	luce antibody-dependent cell-mediated cytotoxicity and
upregulate FCGR3/	A and FcyRIIIA e	xpression in vitro	
Manuscript numbe	r (if known):	AOB-23-42	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	Fundings: Medical and	
	manuscript (e.g., funding,	Health Science and	
	provision of study materials,	Technology Innovation	
	medical writing, article	Project, Chinese Academy	
	processing charges, etc.)	of Medical Sciences (Grant	
	No time limit for this item.	Nos. 2021-12M-I-060 and	
		2021-12M-1-042), the	
		NMPA Key Laboratory of	
		Quality Control of Blood	
		Products (supported by	
		the Guangdong Institute	
		for Drug Control) (Grant	
		No. KF2021011), and the	
		Sichuan Science and	
		Technology Program	
		(Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		

	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
8	Patents planned, issued or	None	
	pending		
_			
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	•	Nana	
10	Leadership or fiduciary role in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	•		
12	Receipt of equipment,	Gang Ye, an employee of	
	materials, drugs, medical	Zhengzhou RAAS Blood	
	writing, gifts or other	Products Co., Ltd,	
	services	provided part of the	
		materials and drugs,	
		including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

ice antibody-dependent cell-mediated cytotoxicity and
-

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date:	31/3/2024	
Your Name:	_Changqing Li	
Manuscript Title:_	Intravenous immunoglo	bulin can induce antibody-dependent cell-mediated cytotoxicity and
upregulate FCGR3	A and FcyRIIIA expressio	on in vitro
Manuscript number	er (if known):A	OB-23-42
•	, , , , , , , , , , , , , , , , , , , ,	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and	
		Technology Program	
		(Grant No. 2022YFS0010).	26 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pastNone	so monuis

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Dauticination on a Data	Nege	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Ye Gang, an employee of Zhengzhou RAAS Blood Products Co., Ltd, provided part of the materials and drugs, including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date:	31/3/2024	
Your Name:	Xi Du	
Manuscript Title	e: Intravenous immunoglobulin can	induce antibody-dependent cell-mediated cytotoxicity and
upregulate FCG	R3A and FcyRIIIA expression in vitro	
Manuscript num	nber (if known): AOB-23-42	
related to the co	ontent of your manuscript. "Related	se all relationships/activities/interests listed below that are " means any relation with for-profit or not-for-profit third rent of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive

medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	30 months

3	Royalties or licenses	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus, manuscript writing or		
6	educational events Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
J	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Ye Gang, an employee of	
	materials, drugs, medical writing, gifts or other	Zhengzhou RAAS Blood Products Co., Ltd,	
	services	provided part of the	
	· ·	materials and drugs,	
		including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date:	31/3/2024	
Your Name:	Shengliang Ye	
Manuscript Title:_	Intravenous immunoglob	pulin can induce antibody-dependent cell-mediated cytotoxicity and
upregulate FCGR3	A and FcyRIIIA expression	in vitro
Manuscript number	er (if known):AO)B-23-42

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	Fundings: Medical and	
	manuscript (e.g., funding,	Health Science and	
	provision of study materials,	Technology Innovation	
	medical writing, article	Project, Chinese Academy	
	processing charges, etc.)	of Medical Sciences (Grant	
	No time limit for this item.	Nos. 2021-12M-I-060 and	
		2021-12M-1-042), the	
		NMPA Key Laboratory of	
		Quality Control of Blood	
		Products (supported by	
		the Guangdong Institute	
		for Drug Control) (Grant	
		No. KF2021011), and the	
		Sichuan Science and	
		Technology Program	
		(Grant No. 2022YFS0010).	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		

3	Royalties or licenses	None	
4	Consulting food	None	
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Command for althoughton	N	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
_			
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	Ye Gang, an employee of	
	materials, drugs, medical	Zhengzhou RAAS Blood	
	writing, gifts or other	Products Co., Ltd,	
	services	provided part of the	
		materials and drugs,	
13	Other financial or non-	including IVIG. None	
13	financial interests	None	
	mandar interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement:

Date: Your Name:	<u></u> Li Ma	3/2024	
		unoglobulin can induce antibody-depende	nt call modiated cutotoxicity and
upregulate FCGR3A			
Manuscript number	r (if known):	AOB-23-42	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Fundings: Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-I-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010).		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None		

3	Royalties or licenses	None	
4	Consulting fees	None	
·			
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
0	Dantisia stiana and Data	Nama	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
	Stock of Stock options		
12	Receipt of equipment,	Ye Gang, an employee of	
	materials, drugs, medical	Zhengzhou RAAS Blood	
	writing, gifts or other services	Products Co., Ltd, provided part of the	
	SCI VICES	materials and drugs,	
		including IVIG.	
13	Other financial or non-	None	
	financial interests		

The authors reported this study was supported by the Medical and Health Science and Technology Innovation Project, Chinese Academy of Medical Sciences (Grant Nos. 2021-12M-I-060 and 2021-12M-1-042), the NMPA Key Laboratory of Quality Control of Blood Products (supported by the Guangdong Institute for Drug Control) (Grant No. KF2021011), and the Sichuan Science and Technology Program (Grant No. 2022YFS0010). The authors also reported receipt of part of the materials and drugs including IVIG from GY.

Please place an "X" next to the following statement to indicate your agreement: